Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma-Reference-Cited by-同舟云学术

Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma

Published:2017-07-24 Issue:5 Volume:182 Page:715-718
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Della Pepa Roberta¹^ORCID,Picardi Marco²,Giordano Claudia¹,Zacheo Irene¹,Pugliese Novella¹,Cerchione Claudio¹,Raimondo Marta¹,Di Perna Maria¹,Troncone Giancarlo²,Ciancia Giuseppe²,Intrieri Mariano³,Pane Fabrizio¹

Affiliation:

1. Department of Clinical Medicine and Surgery; Federico II University; Naples Italy

2. Department of Advanced Biomedical Science; Federico II University; Naples Italy

3. Dipartimento di Medicina e Scienze per la Salute “V. Tiberio”; Università degli studi del Molise; Campobasso Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14856/fullpdf

Reference8 articles.

1. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma;Advani;Journal of Clinical Oncology,2014

2. Revised response criteria for malignant lymphoma;Cheson;Journal of Clinical Oncology,2007

3. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial;Eich;Journal of Clinical Oncology,2010

4. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Eichenauer;Annals of Oncology,2014

5. Long-term course of patients with stage IA nodular lymphocyte-predominant hodgkin lymphoma: a report from the German Hodgkin Study Group;Eichenauer;Journal of Clinical Oncology,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NLPHL: a hummingbird in an owl’s nest;Blood;2023-08-10

2. Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up;Cancers;2021-04-07

3. Lymphoma, Hodgkin’s: Pathology and Genetics;Reference Module in Biomedical Sciences;2018